Skip to main content

Roche launches new coronavirus antibody test

| News

Roche launches new coronavirus antibody test

18.09.2020

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development of vaccines. In addition, a drug from the Basel-based pharma giant has proven to be effective against coronavirus-associated pneumonia.

Roche Headquarter in Basel

Roche is launching a new antibody test that will identify people to have already been infected with coronavirus whose bodies have now developed antibodies against the virus. The test should help in developing vaccines against SARS-CoV-2. In specific terms, the test focuses on antibodies against the spike protein of SARS-CoV-2. The majority of vaccine candidates are aimed at inducing an antibody reaction against the spike protein.

The test will initially be launched in countries that accept that CE mark of the European Union (EU), as detailed in a press release. Roche has, however, also applied for Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). The new test is actually the Basel-based pharma group’s twelfth coronavirus test in its testing portfolio.

In addition to launching a new test, Roche has also announced a success in relation to its drug Actemra/RoActemra. This has proven to be successful in treating patients suffering from pneumonia linked to a coronavirus infection. Patients that were administered Actemra/RoActemra in addition to the standard treatment, were 44 percent less likely to require ventilation or die as the disease progressed in comparison with those patients to receive only standard treatment and a placebo.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

biGENIUS receives 2 million euros for new cloud product

Software company biGENIUS, based in the Basel Area, has secured financing of 2 million euros. This funding was granted following...
Read More

Opterion Health secures investment of 6.5 million Swiss francs

Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which...
Read More

TOLREMO receives 39 million US dollars in investments

TOLREMO Therapeutics has concluded a series A funding round with 39 million US dollars. The biotech company based in Basel...
Read More

Mazars opens tenth Swiss office in Basel

Mazars is now also present in Basel with a subsidiary as of September 1. This is the tenth Swiss location...
Read More

Medtech in Switzerland – bringing together traditional skills and hightech industry

How the intersection of traditional and novel skillsets in the Jura area is propelling Switzerland into a new era of...
Read More

Fondation Botnar supporting further research into pediatric health

The Basel-based Botnar Research Centre for Child Health has received a further donation of 50 million Swiss francs from the...
Read More

Do you have a question? We'd like to hear from you.